The ovarian cancer treatment algorithm is rapidly evolving. For decades, chemotherapy has been the standard of care for ovarian cancer; however, treatment is changing to a targeted approach with the introduction of Roche/Genentech/Chugai’s Avastin and three PARP inhibitors: AstraZeneca’s Lynparza, Clovis Oncology’s Rubraca, and Tesaro’s Zejula. Multiple combination therapies using immune checkpoint inhibitors are in late-phase development for ovarian cancer, and we anticipate that this drug class will significantly change the treatment paradigm.
- What is the size of the drug-treatable ovarian cancer population, and how will the drug-treatment rates change over time?
- What is the current state of treatment in ovarian cancer? Which are the most important drugs? What are interviewed experts’ insights on current treatment options? What are the main unmet needs for ovarian cancer?
- What are the most promising agents in the pipeline, and how will they shape the future of the ovarian cancer market? What notable therapies are progressing in early-phase trials?
- What is the expected impact on the ovarian cancer market with the approvals of Merck KGaA/Pfizer’s Bavencio, Roche/Genentech/Chugai’s Tecentriq, Tesaro’s TSR-042, AstraZeneca’s Imfinzi, Merck & Co.’s Keytruda, and Bristol-Myers Squibb/Ono Pharmaceutical’s Opdivo? What competition will other drug classes pose for immune checkpoint inhibitors?
- What are the drivers and constraints in the ovarian cancer market, and how will the market evolve over the forecast period?
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: More than 20 country-specific interviews with thought-leading medical oncologists supported by survey data collected for this and other DRG research.
Key companies: Roche/Genentech, Tesaro, Clovis Oncology, AstraZeneca, AbbVie, Merck KGaA, Pfizer, Bristol-Myers Squibb, Merck & Co., ImmunoGen.
Key drugs: Avastin (bevacizumab), Lynparza (olaparib), Zejula (niraparib), Rubraca (rucaparib), Talzenna (talazoparib), Opdivo (nivolumab), Bavencio (avelumab), Tecentriq (atezolizumab), Imfinzi (durvalumab), Keytruda (pembrolizumab), TSR-042, mirvetuximab soravtansine, cediranib, VB-111.
Epidemiology: Diagnosed incident cases of epithelial ovarian cancer by stage at diagnosis (I-IIA, IIB-IIC, III, and IV).
Population segments in market forecast: Early-stage first line, advanced-stage first line, second-line platinum-sensitive, second-line platinum-resistant and -refractory, third-line platinum-sensitive, third-line platinum-resistant and -refractory, and fourth and subsequent lines.
Market forecast features: Ten-year, annualized, drug-level sales and patient share of key ovarian cancer therapies through 2027, segmented by brands/generics and epidemiological subpopulations.